Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax

Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax

MP-A08 is a novel sphingosine kinase 1 (SPHK1) inhibitor with activity against acute myeloid leukemia (AML). A rationally designed liposome-based encapsulation and delivery system has been shown to overcome the physicochemical challenges of MP-A08 and enable its effective delivery for improved effic...

Full description

Bibliographic Details
Main Authors: Thao M. Nguyen, Paul Joyce, David M. Ross, Kristen Bremmell, Manasi Jambhrunkar, Sook S. Wong, Clive A. Prestidge
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Pharmaceutics
Subjects:
anti-cancer activity
targeted cancer therapy
combination therapy
drug resistance
acute myeloid leukemia
sphingosine kinase 1 inhibitors
Online Access:https://www.mdpi.com/1999-4923/16/2/209

Internet

https://www.mdpi.com/1999-4923/16/2/209

Similar Items